# Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250

> **NCT00199875** · PHASE1 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 18 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Kidney Neoplasm
- Renal Cancer
- Kidney Cancer

## Interventions

- **DRUG:** Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)

## Key facts

- **NCT ID:** NCT00199875
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07-06
- **Primary completion:** 2013-03-14
- **Final completion:** 2013-03-14
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00199875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00199875, "Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00199875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*